Engineering & Construction
Compare Stocks
5 / 10Stock Comparison
ECG vs PWR vs MTZ vs PRIM vs MYRG
Revenue, margins, valuation, and 5-year total return — side by side.
Engineering & Construction
Engineering & Construction
Engineering & Construction
Engineering & Construction
ECG vs PWR vs MTZ vs PRIM vs MYRG — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Engineering & Construction | Engineering & Construction | Engineering & Construction | Engineering & Construction | Engineering & Construction |
| Market Cap | $8.10B | $112.65B | $32.50B | $5.86B | $6.65B |
| Revenue (TTM) | $3.96B | $29.99B | $15.28B | $7.49B | $3.82B |
| Net Income (TTM) | $223M | $1.12B | $459M | $248M | $142M |
| Gross Margin | 12.4% | 13.6% | 12.1% | 10.4% | 11.9% |
| Operating Margin | 7.4% | 5.8% | 5.6% | 4.9% | 5.1% |
| Forward P/E | 38.1x | 57.4x | 48.6x | 18.1x | 44.0x |
| Total Debt | $106M | $1.19B | $2.80B | $1.28B | $104M |
| Cash & Equiv. | $171M | $440M | $396M | $541M | $150M |
ECG vs PWR vs MTZ vs PRIM vs MYRG — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Oct 24 | May 26 | Return |
|---|---|---|---|
| Everus Construction… (ECG) | 100 | 308.3 | +208.3% |
| Quanta Services, In… (PWR) | 100 | 248.9 | +148.9% |
| MasTec, Inc. (MTZ) | 100 | 335.5 | +235.5% |
| Primoris Services C… (PRIM) | 100 | 172.5 | +72.5% |
| MYR Group Inc. (MYRG) | 100 | 326.2 | +226.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ECG vs PWR vs MTZ vs PRIM vs MYRG
Each card shows where this stock fits in a portfolio — not just who wins on paper.
ECG carries the broadest edge in this set and is the clearest fit for growth exposure.
- Rev growth 31.5%, EPS growth 40.6%, 3Y rev CAGR 11.5%
- 31.5% revenue growth vs MYRG's 8.8%
- 5.6% margin vs MTZ's 3.0%
- +240.8% vs PRIM's +62.4%
PWR is the #2 pick in this set and the best alternative if income & stability and long-term compounding is your priority.
- Dividend streak 7 yrs, beta 1.30, yield 0.1%
- 31.4% 10Y total return vs MTZ's 17.5%
- Lower volatility, beta 1.30, Low D/E 13.2%, current ratio 1.14x
- Beta 1.30, yield 0.1%, current ratio 1.14x
MTZ lags the leaders in this set but could rank higher in a more targeted comparison.
PRIM ranks third and is worth considering specifically for valuation efficiency.
- PEG 0.98 vs MTZ's 16.37
- Lower P/E (18.1x vs 44.0x), PEG 0.98 vs 2.64
Among these 5 stocks, MYRG doesn't own a clear edge in any measured category.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 31.5% revenue growth vs MYRG's 8.8% | |
| Value | Lower P/E (18.1x vs 44.0x), PEG 0.98 vs 2.64 | |
| Quality / Margins | 5.6% margin vs MTZ's 3.0% | |
| Stability / Safety | Beta 1.30 vs ECG's 2.39, lower leverage | |
| Dividends | 0.1% yield, 7-year raise streak, vs PRIM's 0.3%, (3 stocks pay no dividend) | |
| Momentum (1Y) | +240.8% vs PRIM's +62.4% | |
| Efficiency (ROA) | 13.4% ROA vs MTZ's 4.7%, ROIC 31.4% vs 8.9% |
ECG vs PWR vs MTZ vs PRIM vs MYRG — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
ECG vs PWR vs MTZ vs PRIM vs MYRG — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
PRIM leads in 1 of 6 categories
ECG leads 1 • PWR leads 1 • MTZ leads 0 • MYRG leads 0 • 3 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
Evenly matched — ECG and MTZ each lead in 2 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
PWR is the larger business by revenue, generating $30.0B annually — 7.8x MYRG's $3.8B. Profitability is closely matched — net margins range from 5.6% (ECG) to 3.0% (MTZ). On growth, MTZ holds the edge at +34.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $4.0B | $30.0B | $15.3B | $7.5B | $3.8B |
| EBITDAEarnings before interest/tax | $321M | $2.4B | $1.2B | $437M | $261M |
| Net IncomeAfter-tax profit | $223M | $1.1B | $459M | $248M | $142M |
| Free Cash FlowCash after capex | $230M | $1.7B | $179M | $165M | $231M |
| Gross MarginGross profit ÷ Revenue | +12.4% | +13.6% | +12.1% | +10.4% | +11.9% |
| Operating MarginEBIT ÷ Revenue | +7.4% | +5.8% | +5.6% | +4.9% | +5.1% |
| Net MarginNet income ÷ Revenue | +5.6% | +3.7% | +3.0% | +3.3% | +3.7% |
| FCF MarginFCF ÷ Revenue | +5.8% | +5.6% | +1.2% | +2.2% | +6.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | +25.4% | +26.3% | +34.5% | -5.4% | +20.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +58.3% | +51.0% | +4.9% | -60.5% | +106.2% |
Valuation Metrics
PRIM leads this category, winning 7 of 7 comparable metrics.
Valuation Metrics
At 21.5x trailing earnings, PRIM trades at a 81% valuation discount to PWR's 110.4x P/E. Adjusting for growth (PEG ratio), PRIM offers better value at 1.17x vs MTZ's 27.39x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $8.1B | $112.7B | $32.5B | $5.9B | $6.7B |
| Enterprise ValueMkt cap + debt − cash | $8.0B | $113.4B | $34.9B | $6.6B | $6.6B |
| Trailing P/EPrice ÷ TTM EPS | 40.20x | 110.40x | 81.32x | 21.52x | 56.76x |
| Forward P/EPrice ÷ next-FY EPS est. | 38.06x | 57.40x | 48.62x | 18.06x | 44.03x |
| PEG RatioP/E ÷ EPS growth rate | — | 6.40x | 27.39x | 1.17x | 3.40x |
| EV / EBITDAEnterprise value multiple | 27.39x | 45.68x | 32.32x | 13.03x | 28.84x |
| Price / SalesMarket cap ÷ Revenue | 2.16x | 3.97x | 2.27x | 0.77x | 1.82x |
| Price / BookPrice ÷ Book value/share | 12.90x | 12.61x | 9.73x | 3.52x | 10.18x |
| Price / FCFMarket cap ÷ FCF | 90.05x | 69.50x | 113.74x | 17.20x | 28.66x |
Profitability & Efficiency
ECG leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
ECG delivers a 37.2% return on equity — every $100 of shareholder capital generates $37 in annual profit, vs $13 for PWR. PWR carries lower financial leverage with a 0.13x debt-to-equity ratio, signaling a more conservative balance sheet compared to MTZ's 0.84x. On the Piotroski fundamental quality scale (0–9), MTZ scores 8/9 vs PWR's 4/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +37.2% | +13.0% | +14.2% | +15.2% | +22.1% |
| ROA (TTM)Return on assets | +13.4% | +4.8% | +4.7% | +5.6% | +8.7% |
| ROICReturn on invested capital | +31.4% | +11.8% | +8.9% | +13.6% | +18.3% |
| ROCEReturn on capital employed | +30.0% | +11.3% | +10.2% | +16.3% | +19.4% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 4 | 8 | 5 | 8 |
| Debt / EquityFinancial leverage | 0.17x | 0.13x | 0.84x | 0.76x | 0.16x |
| Net DebtTotal debt minus cash | -$65M | $748M | $2.4B | $735M | -$47M |
| Cash & Equiv.Liquid assets | $171M | $440M | $396M | $541M | $150M |
| Total DebtShort + long-term debt | $106M | $1.2B | $2.8B | $1.3B | $104M |
| Interest CoverageEBIT ÷ Interest expense | 16.89x | 6.27x | 4.37x | 21.02x | 39.49x |
Total Returns (Dividends Reinvested)
Evenly matched — PWR and MTZ each lead in 2 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in PWR five years ago would be worth $75,108 today (with dividends reinvested), compared to $32,406 for ECG. Over the past 12 months, ECG leads with a +240.8% total return vs PRIM's +62.4%. The 3-year compound annual growth rate (CAGR) favors MTZ at 67.3% vs MYRG's 47.3% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +78.1% | +70.8% | +81.1% | -17.2% | +88.5% |
| 1-Year ReturnPast 12 months | +240.8% | +132.1% | +183.8% | +62.4% | +175.2% |
| 3-Year ReturnCumulative with dividends | +224.1% | +345.2% | +368.2% | +346.5% | +219.8% |
| 5-Year ReturnCumulative with dividends | +224.1% | +651.1% | +270.5% | +234.4% | +417.6% |
| 10-Year ReturnCumulative with dividends | +224.1% | +3143.9% | +1752.9% | +402.0% | +1680.8% |
| CAGR (3Y)Annualised 3-year return | +48.0% | +64.5% | +67.3% | +64.7% | +47.3% |
Risk & Volatility
PWR leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
PWR is the less volatile stock with a 1.30 beta — it tends to amplify market swings less than ECG's 2.39 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PWR currently trades 95.2% from its 52-week high vs PRIM's 52.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.39x | 1.30x | 1.64x | 1.83x | 1.70x |
| 52-Week HighHighest price in past year | $171.58 | $788.72 | $441.43 | $205.50 | $475.39 |
| 52-Week LowLowest price in past year | $44.97 | $315.45 | $143.93 | $65.23 | $152.10 |
| % of 52W HighCurrent price vs 52-week peak | +92.5% | +95.2% | +93.4% | +52.6% | +89.9% |
| RSI (14)Momentum oscillator 0–100 | 78.9 | 87.0 | 76.5 | 30.3 | 80.7 |
| Avg Volume (50D)Average daily shares traded | 556K | 1.1M | 942K | 1.1M | 306K |
Analyst Outlook
Evenly matched — PWR and PRIM each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: ECG as "Buy", PWR as "Buy", MTZ as "Buy", PRIM as "Buy", MYRG as "Hold". Consensus price targets imply 48.7% upside for PRIM (target: $161) vs -19.9% for MTZ (target: $330). PRIM is the only dividend payer here at 0.29% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Hold |
| Price TargetConsensus 12-month target | $129.33 | $647.23 | $330.25 | $160.63 | $362.00 |
| # AnalystsCovering analysts | 4 | 35 | 36 | 22 | 21 |
| Dividend YieldAnnual dividend ÷ price | — | +0.1% | — | +0.3% | — |
| Dividend StreakConsecutive years of raises | — | 7 | 2 | 2 | 4 |
| Dividend / ShareAnnual DPS | — | $0.40 | — | $0.32 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.1% | +0.2% | +0.2% | +1.2% |
PRIM leads in 1 of 6 categories (Valuation Metrics). ECG leads in 1 (Profitability & Efficiency). 3 tied.
ECG vs PWR vs MTZ vs PRIM vs MYRG: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is ECG or PWR or MTZ or PRIM or MYRG a better buy right now?
For growth investors, Everus Construction Group, Inc.
(ECG) is the stronger pick with 31. 5% revenue growth year-over-year, versus 8. 8% for MYR Group Inc. (MYRG). Primoris Services Corporation (PRIM) offers the better valuation at 21. 5x trailing P/E (18. 1x forward), making it the more compelling value choice. Analysts rate Everus Construction Group, Inc. (ECG) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — ECG or PWR or MTZ or PRIM or MYRG?
On trailing P/E, Primoris Services Corporation (PRIM) is the cheapest at 21.
5x versus Quanta Services, Inc. at 110. 4x. On forward P/E, Primoris Services Corporation is actually cheaper at 18. 1x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Primoris Services Corporation wins at 0. 98x versus MasTec, Inc. 's 16. 37x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — ECG or PWR or MTZ or PRIM or MYRG?
Over the past 5 years, Quanta Services, Inc.
(PWR) delivered a total return of +651. 1%, compared to +224. 1% for Everus Construction Group, Inc. (ECG). Over 10 years, the gap is even starker: PWR returned +31. 4% versus ECG's +224. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — ECG or PWR or MTZ or PRIM or MYRG?
By beta (market sensitivity over 5 years), Quanta Services, Inc.
(PWR) is the lower-risk stock at 1. 30β versus Everus Construction Group, Inc. 's 2. 39β — meaning ECG is approximately 83% more volatile than PWR relative to the S&P 500. On balance sheet safety, Quanta Services, Inc. (PWR) carries a lower debt/equity ratio of 13% versus 84% for MasTec, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — ECG or PWR or MTZ or PRIM or MYRG?
By revenue growth (latest reported year), Everus Construction Group, Inc.
(ECG) is pulling ahead at 31. 5% versus 8. 8% for MYR Group Inc. (MYRG). On earnings-per-share growth, the picture is similar: MYR Group Inc. grew EPS 311. 5% year-over-year, compared to 12. 8% for Quanta Services, Inc.. Over a 3-year CAGR, PRIM leads at 19. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — ECG or PWR or MTZ or PRIM or MYRG?
Everus Construction Group, Inc.
(ECG) is the more profitable company, earning 5. 4% net margin versus 2. 8% for MasTec, Inc. — meaning it keeps 5. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ECG leads at 7. 1% versus 4. 4% for MYRG. At the gross margin level — before operating expenses — PWR leads at 13. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is ECG or PWR or MTZ or PRIM or MYRG more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Primoris Services Corporation (PRIM) is the more undervalued stock at a PEG of 0. 98x versus MasTec, Inc. 's 16. 37x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Primoris Services Corporation (PRIM) trades at 18. 1x forward P/E versus 57. 4x for Quanta Services, Inc. — 39. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRIM: 48. 7% to $160. 63.
08Which pays a better dividend — ECG or PWR or MTZ or PRIM or MYRG?
In this comparison, PRIM (0.
3% yield) pays a dividend. ECG, PWR, MTZ, MYRG do not pay a meaningful dividend and should not be held primarily for income.
09Is ECG or PWR or MTZ or PRIM or MYRG better for a retirement portfolio?
For long-horizon retirement investors, MasTec, Inc.
(MTZ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+1753% 10Y return). Everus Construction Group, Inc. (ECG) carries a higher beta of 2. 39 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MTZ: +1753%, ECG: +224. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between ECG and PWR and MTZ and PRIM and MYRG?
Both stocks operate in the Industrials sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: ECG is a small-cap high-growth stock; PWR is a mid-cap high-growth stock; MTZ is a mid-cap high-growth stock; PRIM is a small-cap high-growth stock; MYRG is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.